HUE034910T2 - Eljárás pentozán-poliszulfát készítményeknek, azok nyersanyagainak és azok elõállítására szolgáló eljárásoknak a minõsítésére - Google Patents

Eljárás pentozán-poliszulfát készítményeknek, azok nyersanyagainak és azok elõállítására szolgáló eljárásoknak a minõsítésére Download PDF

Info

Publication number
HUE034910T2
HUE034910T2 HUE14703299A HUE14703299A HUE034910T2 HU E034910 T2 HUE034910 T2 HU E034910T2 HU E14703299 A HUE14703299 A HU E14703299A HU E14703299 A HUE14703299 A HU E14703299A HU E034910 T2 HUE034910 T2 HU E034910T2
Authority
HU
Hungary
Prior art keywords
pentosan polysulfate
xylose
methyl
glucuronic acid
units
Prior art date
Application number
HUE14703299A
Other languages
English (en)
Inventor
Ferra Lorenzo De
Annamaria Naggi
Maurizio Zenoni
Barbara Pinto
Original Assignee
Chemi Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemi Spa filed Critical Chemi Spa
Publication of HUE034910T2 publication Critical patent/HUE034910T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0057Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Xylans, i.e. xylosaccharide, e.g. arabinoxylan, arabinofuronan, pentosans; (beta-1,3)(beta-1,4)-D-Xylans, e.g. rhodymenans; Hemicellulose; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N24/00Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
    • G01N24/08Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
    • G01N24/088Assessment or manipulation of a chemical or biochemical reaction, e.g. verification whether a chemical reaction occurred or whether a ligand binds to a receptor in drug screening or assessing reaction kinetics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

(12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C08B 37100 (2006 01) 13.09.2017 Bulletin 2017/37 (86) International application number: (21) Application number: 14703299.9 PCT/EP2014/051347 (22) Date of filing: 23.01.2014 (87) International publication number: WO 2014/114723 (31.07.2014 Gazette 2014/31)
(54) METHOD FOR THE QUALIFICATION OF PREPARATIONS OF PENTOSAN POLYSULFATE, RAW MATERIALS AND PRODUCTION PROCESSES THEREOF
VERFAHREN ZUR QUALIFIZIERUNG VON PENTOSANPOLYSULFATPRAPARATEN, ROHSTOFFEN UND HERSTELLUNGSVERFAHREN DAFLIR
PROCEDE POUR LA QUALIFICATION DE PREPARATIONS DE POLYSULFATE DE PENTOSANE, MATIERES PREMIERES ET DE PROCEDES DE PRODUCTION ASSOCIES (84) Designated Contracting States: (56) References cited: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB EP-A1-0 184 480 WO-A1-2009/087581 GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO WO-A1-2012/101544 WO-A1-2012/114349
PL PT RO RS SE SI SK SM TR • AHRGREN L ET AL: "Pyridinium substitution (30) Priority: 24.01.2013 ITMI20130112 during the sulfation of polysaccharides in the
presence of pyridine", CARBOHYDRATE (43) Date of publication of application: POLYMERS, APPLIED SCIENCE PUBLISHERS, 02.12.2015 Bulletin 2015/49 LTD. BARKING, GB, vol. 16, no. 2,1 January 1991 (1991-01-01), pages211-214, XP024147748, ISSN:
(73) Proprietor: Chemi SPA 0144-8617, DOI: 10.1016/0144-8617(91)90104-K 20092 Cinisello Balsamo (Ml) (IT) [retrieved on 1991-01-01] cited in the application • TELEMAN A ET AL: "Characterization of (72) Inventors: 0-acetyl-(4-0-methylglucurono)xylan isolated
• DE FERRA, Lorenzo from birch and beech", CARBOHYDRATE 1-03010 Patrica (FR) (IT) RESEARCH, PERGAMON, GB, vol. 337, no. 4,1 • NAGGI, Annamaria February 2002 (2002-02-01), pages 373-377, I-20025 Legnano (Ml) (IT) XP004335940, ISSN: 0008-6215, DOI: • ZENONI, Maurizio 10.1016/S0008-6215(01)00327-5 cited in the 1-03010 Patrica (FR) (IT) application • PINTO, Barbara · TAUBNER L M ET AL: "Structure of the Flexible 03010 Patrica, FR (IT) Amino-Terminal Domain of Prion Protein Bound
to a Sulfated Glycan", JOURNAL OF (74) Representative: Longoni, Alessandra MOLECULAR BIOLOGY, ACADEMIC PRESS, AL & Partners Sri UNITED KINGDOM, vol. 395, no. 3, 22 January
Via C. Colombo ang. Via Appiani 2010 (2010-01-22), pages 475-490, XP026827929, (Corte del Cotone) ISSN: 0022-2836, DOI: 20831 Seregno (MB) (IT) 10.1016/J.JMB.2009.10.075 [retrieved on 2009-11-10]
Description [0001] The present invention relates to methods and products based on the identification of characterizing structural units of pentosan polysulfate and the corresponding xylan without sulfate groups, in particular to products obtained by a method of qualification and selection of production processes, raw materials, intermediates, production batchs of pentosan polysulfate based on the identification of said characterizing structural units.
State of the art [0002] Several pharmaceutical products (for example Elmiron®, CCRIS 8869, Fibrase®, Fibrezym®, HSDB 7294, Hoe/bay 946, NSC 626201, SP-54, Thrombocid®, PZ68, Hemoclar®, Fibrocid® and Tavan®) contain, as active ingredient, pentosan polysulfate, a polysaccharide which main skeleton is constituted by sequences of sulfated xylose units linked together through a glycosidic β-(1->4) bond.
[0003] Being obtained from xylanes extracted by high trees such as beech, ramifications of 4-O-methyl-glucuronic acid are present and distributed in a not necessarily regular manner.
[0004] The chemical structure of pentosan polysulfate reported in the technical and scientific literature corresponds to the following formula 1:
Formula 1 wherein R is H or S03Na.
[0005] The commercial product Elmiron® has a high sulfation degree and its molecular weight is 4000-6000 Dalton. Therefore pentosan polysulfate is made of a mixture of sulfated polysaccharides different each other for chain lengths and branching. Pentosan polysulfate is used in the pharmaceutical field as anticoagulant and in the treatment of interstitial cystitis. It also shows several other biological activities including anti-tumor and anti-metastatic activity, antiviral and anti-inflammatory activity. It has been proposed as a therapeutic agent in the prevention and treatment of Prion Disease. It has effect in inhibiting the growth of the calcium oxalate crystals which lead to the formation of kidney stones. It also showed efficacy as anti-arthritic agent in animals suffering from osteoarthritis.
[0006] The polymerization degree and the structural variety can strongly influence the biological, immunological and toxicological activity of polysaccharides and of sulfated polysaccharides [T.Astrup Scand J Clin Lab Invest 137 (1952)].
[0007] A deep knowledge of the structural characteristics of pentosan polysulfate is therefore extremely important to ensure the therapeutic efficacy and safety of the pharmacological treatments which use it.
[0008] Because of the natural origin of the raw material and because of the processes of isolation and production, structural groupings which contribute to increase its structural complexity may be present on the polymer chain of xylan polysulfate. For example, in addition to sulfated xylose and sulfated 4-O-methyl-glucuronic acid, different monosaccharide units may be present.
[0009] Furthermore different sulfated and not sulfated polymeric species may be present, such as for example those deriving from other polysaccharides present in the natural source of the raw material.
[0010] In particular, the structural complexity of pentosan polysulfate may further increase depending on the method for the extraction of xylan from the natural source of the raw material. In fact such extraction method, depending from its selectivity, will provide xylan with different characteristics and different purity degrees. Moreover, during the transformation of xylan into the final product, it is possible that new impurities are introduced and that the transformation of those present or the introduction of new chemical groups in the polymer structure occur. These factors may also contribute to the complexity of the product as a whole.
[0011] Currently, the structural characterization of pentosan polysulfate has not been brought to the level of details required in view of the complexity of the product and therefore it is not suitable to the need of ensuring quality standard and equivalence of the production of the drugs on the market and to the proof of equivalence of generic pharmaceutical products.
[0012] A progress in the analytical characterization of pentosan polysulfate and in the identification of its characteristic structural units is therefore urgently needed.
[0013] In the present context, characteristic structural unit means a part of the chemical structure of pentosan polysulfate or of xylan used for its preparation. Based on said characteristic structural unit various compositions or preparation methods of these polysaccharides can be qualified.
[0014] Qualification means the acknowledgement of the suitability of a polysaccharide composition or of a method for its preparation for the manufacturing of a pharmaceutical product for human use.
Summary of the invention [0015] The invention is based on the discovery that the structure of pentosan polysulfate in the pharmaceutical products is characterized by the presence of some characteristic structural units that have not been so far identified in the chemical structure of formula 1 reported in the literature.
[0016] Such characteristic structural units have been identified by the Applicant and are acetylated monosaccharide units, and in particular units of acetylated xylose substituted with 4-O-methyl-glucuronic acid.
[0017] Therefore the present invention relates to methods for identifying the presence of said characteristic structural units in pentosan polysulfate and in xylan and to their application for the qualification of preparations of pentosan polysulfate, their raw materials such as xylan and their production processes.
[0018] A further object of the present invention is a method for the preparation of pentosan polysulfate and xylan comprising at least one qualification step based on said characteristic structural units.
Brief description of the drawings [0019]
Fig. 1 - 1H-NMR spectrum of pentosan polysulfate
Fig. 2 - (A) FISQC NMR spectrum of pentosan polysulfate (XS) and (B) of xylan without sulfate groups obtained by desulfation of pentosan polysulfate (XSDS)
Fig. 3 - Maldi TOF spectrum of xylan XSDS
Detailed description of the invention [0020] In a first aspect the present invention relates to polysaccharides of formula 2
wherein R is H or S03Na; G is H, S03Na or acetyl; obtained by a method comprising at least one identification or quantification step of acetylated monosaccharide units, and in particular units of acetylated xylose substituted with 4-O-methyl-glucuronic acid.
[0021] Pentosan polysulfate of formula 2 is characterized by the presence of xylose units substituted with 4-O-methyl-glucuronic acid and acetylated (G=acetyl) which represent characteristic structural units identified by the Applicant.
[0022] In a further aspect, the present invention relates to methods for identifying the presence of said characteristic structural units in pentosan polysulfate as well as in xylan and to their application for the qualification of preparations of pentosan polysulfate, their raw materials (xylans) and their production processes.
[0023] In a further embodiment, the present invention relates to the xylan of formula 2 wherein R is hydrogen and G is hydrogen or acetyl characterized by the presence of xylose units substituted with 4-O-methyl-glucuronic acid and acetylated (G=acetyl) which represent characteristic structural units identified by the Applicant.
[0024] The invention is based on the discovery that the structure of pentosan polysulfate present in pharmaceutical products is characterized by the presence of some characteristic structural units which may be correlated to the therapeutic efficacy and safety of pentosan polysulfate.
[0025] In the present context, the terms "pentosan polysulfate for pharmaceutical use", "pharmaceutical products containing pentosan polysulfate" and "commercial pentosan polysulfate" mean products on the market and/or known products which contain pentosan polysulfate as active ingredient for pharmaceutical use, with preferred reference to the medicinal product marketed under the name Elmiron®. By analyzing samples of commercial pentosan polysulfate by 1H-NMR spectroscopy, in particular Elmiron®, the signals corresponding to the polysulfate structure with high sulfation degree of formula 1 wherein the R groups are mainly sulfate groups have been detected, and furthermore it has been unexpectedly found that the spectrum shows the presence of signals at about 2.3 ppm corresponding to the presence of acetyl groups and the splitting of some peaks. In particular the splitting of the signal at about 3.48 ppm corresponding to the methoxy group of the 4-O-methyl-glucuronic acid units stands out (Figure 1). Signals in the region 8.8-9.3 ppm due to pyridinium groups arising from the sulfation procedure used for the production of pentosan polysulfate for pharmaceutical use have been also detected.
[0026] The presence of pyridinium groups bound to pentosan polysulfate is reported in the literature, for example in W003073106 and Carbohydrate Polymers 16 (1991) 211-214.
[0027] On the contrary, the splitting of the 1H-NMR signal relative to the methoxy group of the unit of 4-O-methyl-glucuronic acid and the presence of signals corresponding to acetyl groups are not expected on the basis of the chemical structure of pentosan polysulfate reported in the technical and scientific literature and represented by formula 1.
[0028] The Applicant has taken into consideration the possibility that the NMR signal at about 2.3 ppm was caused by traces of solvents or salts used in the production process of pentosan polysulfate and not completely removed during purification. Chemical analyses such as the determination of the free anions by HPLC, gas chromatographic analysis of residual solvents and comparison of the 1H-NMR chemical shifts in the 2.3 ppm region allowed to exclude the presence of species such as acetate ion and solvents such as acetic acid and ethyl acetate in such quantities to justify the presence of the 1H-NMR signal at about 2.3 ppm in the spectrum of pentosan polysulfate shown in Figure 1.
[0029] Said 1FI-NMR signal was then attributed to the presence of an acetyl group chemically bound to pentosan polysulfate.
[0030] The xylan from beech is used as a raw material in the manufacture of pharmaceutical products of pentosan polysulfate for human use.
[0031] The native xylan from beech is constituted by chains of beta 1-4 xylose partially acetylated at positions 2 and 3; there are also units of alpha 4-O-methyl-glucuronic acid bound to position 2 of the xylose unit of the polysaccharide chain [see for example Carbohydrate Research 337 (2002) 373-377], The processes commonly used for the isolation of xylan from beech involve the use of strongly alkaline solutions in which the xylan shows a quite good solubility; under these conditions the complete deacetylation of xylan occurs.
[0032] It is therefore surprising to have identified the presence of the acetyl function bound to pentosan polysulfate; in view of the potential implications on the biological and toxicological activities of pentosan polysulfate for pharmaceutical use, the acetyl group is a characterising structural units of the product.
[0033] For the structural identification of the unit characterizing pentosan polysulfate, experiments based on NMR spectroscopy were carried out exploiting the potential of this technique in the structural analysis of polysaccharides and sulfated polysaccharides.
[0034] The NMR spectrum of Fleteronuclear Single Quantum Coherence (FISQC) of samples of pentosan polysulfate shows a series of signals corresponding to the different positions of the units of xylose and 4-O-methyl-glucuronic acid of the polysaccharide (Figure 2-A).
[0035] The attribution of each detected signals to specific chemically defined positions is made difficult by the large number of structural combinations similar to each other present in the polysaccharide, and therefore by the presence of a multitude of signals in the FISQC NMR spectrum; these signals are close each other in the spectrum and partially overlapped. The multiplicity of positions chemically similar, but spectroscopically distinguishable derives from the combination of the various possible patterns of substitution with functional groups (sulfate, hydrogen or acetyl) or ramifications of the xylose unit of the chain, reducing end or non-reducing end. The signals corresponding to the units of 4-O-methyl-glucuronic acid which are present in the various possible structural variety overlap to the signals corresponding to the above reported species.
[0036] This situation hampers the work of attribution of all the FISQC NMR signals to specific structural contexts.
[0037] By repeating the NMR experiment on samples of pentosan polysulfate for pharmaceutical use that had been subjected to a procedure of exhaustive desulfation to obtain the corresponding xylan without sulfate groups, a higher resolution of the signals and the simplification of the FISQC spectrum was found. The chemical environments corresponding to the different positions of the polysaccharide are apparently more differentiated each other in the desulfated product than in the sulfated product. In addition, the removal of the sulfate groups reduces the structural variability of the different constituent units of the polysaccharide taking into consideration that also in pentosan polysulfate, notwith standing its high sulfation degree, not completely sulfated saccharide units are present and that each of these can be associated with a series of NMR signals. Therefore a reduction of the structural variety corresponds to a simplification of the NMR spectrum (Figure 2-B).
[0038] Therefore it was possible, by combining several NMR techniques such as analysis HSQC, HMBC, TOCSY and COSY, to find that the acetyl group is not equally distributed between the positions 2 and 3 of the repeating units which constitute pentosan polysulfate, but it is mainly present at position 3 of the repeating units of xylose.
[0039] Furthermore the Applicant found that said acetyl groups are mainly bound to the position 3 of the xylose units which have also a 4-O-methyl-glucuronic acid unit in position 2.
[0040] The Applicant has therefore determined experimentally that pentosan polysulfate for pharmaceutical use is characterized by the presence of units of xylose substituted with 4-O-methyl-glucuronic acid and acetylated which represent structural characteristic units.
[0041] This determination of the structural units of the polysaccharide has been confirmed by the mass spectroscopy analysis of the xylan obtained by exhaustive desulfation of pentosan polysulfate on which a Maldi TOF analysis was carried out. Fig. 3 shows the resultant spectrum showing the presence of three different sets of sequences that differ by the value corresponding to the mass of the repeating unit of xylose (132 daltons), having the following masses: the first series having peaks with mass of 701,833, 965,1165 Da, etc. corresponding to oligomers of polyxylan (Xyl)n the second series having peaks with mass of 759, 891,1023,1155 Da, etc. corresponding to oligomers of polyxylan with a branch of 4-O-methyl-glucuronic acid (Xyl)n-(Xyl-GlcAOMe)-(Xyl)m the third series having peaks with mass of 801,933, 1065 Da, etc. corresponding to oligomers of polyxylan with a branch of 4-O-methyl-glucuronic acid in which an acetyl group is also present (Xyl)n-(Xyl-OAc-GlcAOMe)-(Xyl)m [0042] The results obtained from the characterization by MALDI TOF mass spectroscopy show that the acetyl group is bound to the structure of the polysaccharide. Said results also show that the acetyl group is mainly present in species in which there is also a 4-O-methyl-glucuronic acid group. By suitably combining the results of the NMR analysis it was possible to fill in the following Table 1 with the assignment of the NMR signals relative to the sample obtained by desulfation procedure.
Table 1
(continued)
[0043] By using the information collected from the analysis of samples of xylan obtained by desulfation of pentosan polysulfate it was possible to complete the assignment of the NMR signals for the not desulfated product. Combining this information with the results of the NMR experiments, such as HSQC, HMBC, TOCSY and COSY, carried out directly on not desulfated samples the results of the structural analysis were confirmed and the following table 2 has been prepared on the basis of the 1H and 13C NMR signals of pentosan polysulfate.
Table 2
(continued)
[0044] Based on the obtained results, the Applicant has attributed to pentosan polysulfate for pharmaceutical use the structure of formula 2:
wherein R is H or SOsNa G is H, S03Na or acetyl; wherein the structural group G which can be an acetyl group, is present.
[0045] The Applicant has then experimentally defined that pentosan polysulfate for pharmaceutical use is characterized by the presence of xylose units substituted by 4-O-methyl-glucuronic acid and acetylated (G=acetyl) as characteristic structural units.
[0046] This high structural specificity is a characterizing feature of pentosan polysulfate used as active pharmaceutical ingredient for human use.
[0047] The identification of this specific structural unit of pentosan polysulfate has several useful applications such as the selection of the method of isolation of the raw material (xylan from beech), the evaluation of the process for the transformation of xylan into the final product comprising the steps of depolymerization and sulfation, the procedures for the isolation and purification of the resultant pentosan polysulfate, the evaluation of batches of the production of intermediates and final product.
[0048] The above features has a further practical application of the invention consisting in the xylan obtained by the desulfation of pentosan polysulfate or by other methods and represented by formula 2 wherein R is hydrogen and G is hydrogen or acetyl as well as in the use of said xylan as raw material for the preparation of pentosan polysulfate for pharmaceutical use by preserving its structural units.
[0049] A further practical embodiment of the present invention is the possibility to make more meaningful the process controls at different production steps by linking them to specific structural parameters.
[0050] These factors will be taken into account in the production and marketing of pentosan polysulfate for pharmaceutical use and should also be considered as part of the registration process of the product before the regulatory authorities, such as the FDA, for the authorization of generic versions of pentosan polysulfate.
[0051] These assessments are not limited to the check of the presence of the characteristic structural unit, but also to its quantification. For this purpose, NMR spectroscopy may still be used. Through this technique we have found that the presence of the acetyl groups is mainly in the position 3 of the repetitive xylose units. In addition we have found that said acetyl groups are mainly bound to the position 3 of xylose units also having a 4-O-methyl-glucuronic acid unit bound in position 2. By integration in the HSQC spectrum of different samples of xylan and pentosan polysulfate, the amount of xylose units having both an acetyl group and a 4-O-methyl-glucuronic acid unit was determined (determined by integrating the signal relative to the position 3 of the specified xylose unit), with respect to the total xylose units bearing a 4-O-methyl-glucuronic acid unit in position 2 (integrating the corresponding signals of the positions 1). Based on the obtained data, the Applicant has been able to determine that the content of xylose units substituted with 4-O-methyl-glucuronic acid which also have an acetyl group in the pentosan polysulfate for pharmaceutical use and in the corresponding xylan without sulfate groups is at least 20%, preferably between 35% and 70%, with respect to the total amount of the present residues of 4-O-methyl-glucuronic acid.
[0052] Therefore, preferred features of the present invention are xylan and pentosan polysulfate of formula 2 containing at least 20% of xylose units substituted with a 4-O-methyl-glucuronic acid that are acetylated as characteristic structural units obtained with a method that comprises at least one qualification step based on said characteristic structural units.
[0053] In further particularly preferred aspects the present invention relates to xylan and pentosan polysulfate of formula 2 containing between 35% and 70% of xylose units substituted with a 4-O-methyl-glucuronic acid that are acetylated as characteristic structural units obtained with a method that comprises at least one qualification step based on said characteristic structural units.
[0054] This quantitative evaluation involves multiple advantages such as the selection of the method of isolation of the raw material (xylan from beech), the evaluation of the transformation process of xylan into the final product comprising the steps of depolymerization and sulfation, the isolation and purification procedures of the resultant pentosan polysulfate, the assessment of production batches of raw material, intermediate and final product.
[0055] Then, also these structural features related to the quantification of the structural unit will be taken into account for the production and marketing of pentosan polysulfate for pharmaceutical use; furthermore these structural features also have to be considered as part of the registration process of the product before the regulatory authorities, such as for example the FDA, for the authorization of generic versions of pentosan polysulfate.
[0056] The identification of the characteristic structural units of xylan and pentosan polysulfate was carried out as previously described by using advanced spectroscopic techniques, however, the methods of the present invention are not limited to these techniques, but also include the use of the information relating to the presence and quantification of such characteristic structural unit determined by any analytical technique such as IR spectroscopy, HPLC analysis, analysis of the products of depolymerization, ELISA, capillary electrophoresis.
[0057] The absence or the presence and the quantification of the signals of the characteristic structural unit are determined by any method that allows the identification in the preparation of xylan or xylan sulfate as such, their fractions or their hydrolysis products. For example, one or more of the following methods maybe used: nuclear magnetic resonance (NMR), mass spectrometry, for example matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS), electrospray ionization mass spectrometry (ESI MS), coupled or not to chromatographic separation techniques (for example size exclusion, ionic, etc.). The methods of the present invention preferably use NMR spectroscopy, even more preferably the HSQC NMR spectroscopy.
[0058] The use of the information relating to the presence and the quantification of the characteristic structural units for the qualification and the selection of batches of pharmaceutical pentosan polysulfate active ingredient is of particular importance. In that case, on the basis of this information the decision whether to approve, reject, or possibly rework batches of pentosan polysulfate for pharmaceutical use may be taken.
[0059] In order to better illustrate the present invention without limiting it, the following examples are now given. Example 1
Procedure for the desulfation of pentosan polysulfate [0060] 500 mg of pentosan polysulfate (Elmiron®) were converted into the acid form by treatment with an ion exchange resin (Amberlite IR 120 H+) and the resultant solution (50 mL) was neutralized with pyridine and then lyophilized. The pyridine salt was dissolved in a solution of DMSO (2 mL) containing 10% of H20 and the solution was heated at 80°C for 4 hours. After this time the solution was added to a volume of water at least 3 times higher and cooled. The xylan sample without sulfate groups was isolated after suitable purification operations (precipitation, dialysis, Size Exclusion Chromatography). This procedure was repeated to prepare at least 3 samples (P5146, P5211 and P5212).
Example 2
Procedure for the recordal of NMR spectra [0061] The spectra were recorded with a spectrometer Bruker AVANCE 500 or 600 MHz equipped with a cryoprobe.
[0062] Sample preparation: about 20 mg were dissolved in 0.6 mL of D20 (99.9% deuterated water D) or in a mixture D20/DMSO (deuterated dimethyl sulfoxide) in 1:9 ratio and transferred into a tube for NMR analysis of 5 mm. The 1H-NMR spectra were acquired at a temperature of 303 Kelvin with pre-saturation of the water signal with an interval of recycle of 12 s, for a number of scans from 16 to 24 calibrating the spectrum with respect to TSP.
Example 3
Identification of characteristic parameters of the structure of pentosan polysulfate or xylan without sulfate groups via two-dimensional (2D) NMR
[0063] The 2D NMR experiments can be homonuclear (for example COSY, TOCSY, etc.) or heteronuclear (HSQC, HSQC-DEP, HMQC, HMBC, etc.). All the 2D spectra (HSQC, HMBC, COSY, TOCSY and HSQC-TOCSY) were carried out on samples prepared under the same conditions described for the 1H-NMR spectrum and acquired at a temperature of 303 Kelvin, calibrating the spectrum with respect to TSP if performed in D20 solvent and with respect to the peak of DMSO solvent, if the spectra were carried out in DMSO/D20 solvent.
[0064] Two-dimensional spectra DQF (double-quantum-filter)-COSY and 2D-TOCSY were acquired using from 16 to 24 scans per set of 2048X512 data points with zero filling in F1 (4096X2048), a function "shifted (π/3) squared cosine" was applied before the Fourier transform. The spectrum HSQC (heteronuclear single-quantum coherence) was obtained in "phase sensitivity enhanced pure-absorption mode" with decoupling during acquisition. The dimensions of the matrix were of 1024X320 data points that were "zero-filled" at 4096X2048 by applying a cosine square function before the Fourier transform.
[0065] A HMBC experiment on a xylan sample without sulfate groups showed a long range correlation between the signal of the residue of xylose and a carboxyl group of the acetyl group.
[0066] This signal was identified through an experiment COSY and HSQC-TOCSY as the position 3 of a xylose residue carrying the acetyl group. The position 2 of said residue was found to correlate in the HMBC spectrum with a residue of glucuronic acid highlighting the presence of glucuronic acid in the position 2 and of the acetyl group in position 3 of the same xylose residue. This explained the splitting of the signals relating to the glucuronic acid residue in positions 1,3, 4 and 5 in addition to the splitting of the signal of the Ο-Me group.
[0067] The two-dimensional experiments described above allowed also to identify the chemical shifts of the reduc-ing/non-reducing residues and the characteristic parameters of the structure as shown in Table 1. The HMBC experiment on the sample of Elm iron® (pentosan polysulfate) showed similar long-range correlations between the signal corresponding to the position 3 of the acetylated xylose residue and the carboxyl group of the acetyl group. The two-dimensional spectra also allowed the assignment of the signals reported in Table 2.
Example 4
Quantification of characteristic parameters of the structure of xylan without sulfate groups and pentosan polysulfate [0068] The absence or the presence and the quantification of the signals of the characteristic structural units were determined with 2D-NMR spectra of xylans without sulfate groups obtained by desulfation as described in example 1 and with the spectra of pentosan polysulfate and were associated with the presence of a signal in the region corresponding to residues of xylose bearing the acetyl group. It resulted that the acetyl group was not distributed in an equivalent manner between the positions 2 and 3 of the repetitive units forming the polysaccharide structure, but was mainly concentrated in the position 3 of the repetitive xilose units.
[0069] It also resulted that these acetyl groups were mainly bound to the position 3 of xylose units bearing also a 4-O-methyl-glucuronic acid unit in position 2. The presence of the signal meant that the characteristic structural unit can be detected and quantified by integration as % in comparison with the total number of present residues of 4-O-methyl-glucuronic acid.
[0070] The following table 3 reports the values of the quantification carried out on different samples.
Table 3
[0071] The quantification of the percentage of the xylose units substituted with 4-O-methyl-glucuronic acid that are bearing also the acetyl group (%Ac) was calculated by processing the integrals of the NMR signals according to the formula: wherein:
|C3-XylAc = integral of the signal of the position 3 of the xylose bearing the acetyl group in 3 and the 4-O-methyl-glucuronic acid in 2 JEC1-Glc = integral of the sum of the signals of the position C1 of 4-O-methyl-glucuronic acid, bound to xylose with acetyl group and bound to xylose without acetyl group.
[0072] The analysis was also carried out on a sample of pentosan polysulfate for pharmaceutical use from a different manufacturer and bought on the Indian market. The signals of OAc group at 2.3 ppm, of C3-XylAc group at 5.25/75.96 ppm and of C1-XylAc group at 5.00/106.73 ppm were not detected in its NMR spectra.
[0073] The NMR analysis of this sample showed the presence of structures which are not present in pentosan sulfates extracted from the commercial product Elmiron®, associated with signals in different regions of the spectrum, and in particular between 5.8/6.2 ppm and 95/115 ppm, highlighting the diagnostic capability of this technique for structural investigation.
Example 5
Mass analysis of xylan [0074] The mass spectrometry was applied as an orthogonal technique of structural analysis. The xylan sample without sulfate groups obtained as described in example 1 was analyzed via MALDI mass spectrometry following the procedure below. The sample was dissolved in H20 at a concentration of approximately 0.5 mg/mL. 1 microliter of the analyte solution was added to 5 microliters of a solution of DHB matrix at a concentration of 10 mg/mL in 80% EtOH. 1 microliter of the mixture was placed on the target and analyzed with a spectrometer Bruker Daltonics Autoflex MALDI TOF in positive polarity and in reflectron mode.
Claims 1. A method for the preparation of polysaccharides of formula
wherein R is H or SOgNa G is H, SOgNa or acetyl comprising at least one identification or quantification step of the xylose units substituted with 4-O-methyl-glucuronic acid and acetylated (G=acetyl). 2. A method according to claim 1 wherein the polysaccharide contains at least 20% of xylose units substituted with 4-O-methyl-glucuronic acid that are acetylated (G=acetyl). 3. A method according to claim 2 wherein the polysaccharide contains from 35% to 70% of xylose units substituted with 4-O-methyl-glucuronic acid that are acetylated (G=acetyl). 4. A method according to anyone of the previous claims wherein said identification or quantification step is carried out by NMR spectroscopy. 5. A method according to claim 4 wherein the identification comprises the detection of one or more signals at 2.17(11-1), 23.89(130); 176.60(130); 4.63(1 H), 104.17(130); 3.68(1 H), 78.41(130); 5.09(1H), 76.99(130); 3.78(1 H), 79.36(130); 4.10(1H), 65.96(130); 3.37(1H), 65,95(130); 5.30(1H), 101.16(130); 3.58(1 H), 73.93(130); 3.80(1 H), 75.22(130); 3.82(1H), 84.46(130); 4.64(1 H), 72.67(130); 3.49(1 H), 63.00(130); 177.00(130); 2.30(1 H), 23.37(130); 176.14(130); 5.00(1 H), 106.73(130); 3.93(1 H), 76.85(130); 5.25(1H), 75.96(130); 4.14(11-1), 76.79(130); 4.29(1 H), 65.60(130); 3.69(1 H), 65.60(130); 5.76(1 H), 96.99(130); 4.31 (1H), 77.76(130); 4.42(1 H), 80.83(130); 3.45(1 H), 84.04(130); 3.92(1 H), 75.71(130); 3.48(1 H), 63.61(130); 178.44(130). 6. A method according to claim 4 wherein the quantification is calculated according to the formula %Ac= jC3-XyIAc/ΣΟΙ-Glc, wherein |C3-XylAc = integral of the signal of the position 3 of the xylose bearing the acetyl group in 3 and the 4-O-methyl-glucuronic acid in 2 and jECI-GIc = integral of the sum of the signals of the position C1 of 4-O-methyl-glucuronic acid, bound to xylose with acetyl group and bound to xylose without acetyl group. 7. A method according to anyone of the previous claims for the preparation of pentosan polysulfate. 8. A method according to anyone of the previous claims for the preparation of xylan. 9. A method according to anyone of the previous claims for the qualification of pentosan polysulfate for pharmaceutical use, raw materials thereof and manufacturing products thereof. 10. A polysaccharide of formula
wherein R is H and G is H or acetyl; and at least 20% of the xylose units substituted with 4-O-methyl-glucuronic acid have also G=acetyl. 11. A polysaccharide according to claim 10 wherein from 35% to 70% of the xylose units substituted with 4-O-methyl-glucuronic acid have also G=acetyl.
Patentanspriiche 1. Verfahren zur Herstellung von Polysacchariden der Formel
wobei R H oder S03Na ist G H, S03Na oder Acetyl ist umfassend mindestens einen Identifizierungs-oder Quantifizierungsschritt der Xyloseeinheiten, die mit4-0-Methyl-glucuronsäure substituiert und acetyliert (G=Acetyl) sind. 2. Verfahren nach Anspruch 1, wobei das Polysaccharid mindestens 20 % Xyloseeinheiten enthält, die mit 4-O-Me-thylglucuronsäure substituiert sind, die acetyliert (G=Acetyl) sind. 3. Verfahren nach Anspruch 2, wobei das Polysaccharid 35 % bis 70 % Xyloseeinheiten enthält, die mit 4-0-Methyl-glucuronsäure substituiert sind, die acetyliert (G=Acetyl) sind. 4. Verfahren nach einem der vorhergehenden Ansprüche, wobei der Identifizierungs- oder Quantifizierungsschritt durch eine NMR-Spektroskopie ausgeführt wird. 5. Verfahren nach Anspruch 4, wobei die Identifizierung die Detektion von einem oder mehreren Signalen bei 2,17(11-1), 23,89(13C); 176,60(13C); 4,63(1 H), 104,17(130); 3,68(1 H), 78,41(130); 5,09(1H), 76,99(130); 3,78(1 H), 79,36(130); 4,10(1 H), 65,96(130); 3,37(1H), 65,95(130); 5,30(1H), 101,16(130); 3,58(1 H), 73,93(130); 3,80(1H), 75,22(130); 3,82(1 H), 84,46(130); 4,64(1 H), 72,67(130); 3,49(1H), 63,00(130); 177,00(130); 2,30(1H), 23,37(130); 176,14(130); 5,00(1H), 106,73(130); 3,93(1H), 76,85(130); 5,25(1H), 75,96(130); 4,14(1H), 76,79(130); 4,29(1 H), 65,60(130); 3,69(1H), 65,60(130); 5,76(1H), 96,99(130); 4,31 (1H), 77,76(130); 4,42(1H), 80,83(130); 3,45(1H), 84,04(130); 3,92(1 H), 75,71(130); 3,48(1H), 63,61(130); 178,44(130) umfasst. 6. Verfahren nach Anspruch 4, wobei die Quantifizierung gemäß der Formel %Ac= |C3-XylAc/|zC1-Glc berechnet wird, wobei jC3-XylAc = Integral des Signals der Position 3 der Xylose, welche die Acetylgruppe in 3 und die 4-0-Methylglucuronsäure in 2 trägt und jlC1-Glc = Integral der Summe der Signale der Position C1 von 4-O-Methylglu-curonsäure, gebunden an Xylose mit einer Acetylgruppe und gebunden an Xylose ohne eine Acetylgruppe. 7. Verfahren nach einem der vorhergehenden Ansprüche zur Herstellung von Pentosanpolysulfat. 8. Verfahren nach einem der vorhergehenden Ansprüche zur Herstellung von Xylan. 9. Verfahren nach einem der vorhergehenden Ansprüche zur Qualifizierung von Pentosanpolysulfat zur pharmazeu tischen Verwendung, Rohmaterialien davon und Herstellungsprodukten davon. 10. Polysaccharid der Formel wobei
R H ist und G H oder Acetyl ist; und mindestens 20 % der Xyloseeinheiten, die mit 4-O-Methylglucuronsäure substituiert sind, ebenso G=Acetyl aufweisen. 11. Polysaccharid nach Anspruch 10, wobei 35 % bis 70 % der Xyloseeinheiten, die mit 4-O-Methylglucuronsäure substituiert sind, ebenso G=Acetyl aufweisen.
Revendications 1. Procédé de préparation de polysaccharides de formule
dans laquelle R représente H ou SOsNa G représente H, SOsNa ou acétyle comprenant au moins une étape d’identification ou de quantification des motifs de xylose substitués par un groupe acide 4-O-méthyl-glucuronique et acétylés (G=acétyle). 2. Procédé selon la revendication 1, ledit polysaccharide contenant au moins 20 % de motifs de xylose substitués par un groupe acide 4-O-méthyl-glucuronique qui sont acétylés (G=acétyle). 3. Procédé selon la revendication 2, ledit polysaccharide contenant de 35 % à 70 % de motifs de xylose substitués par un groupe acide 4-O-méthyl-glucuronique qui sont acétylés (G=acétyle). 4. Procédé selon l’une quelconque des revendications précédentes, ladite étape d’identification ou de quantification étant effectuée par spectroscopie NRM. 5. Procédé selon la revendication 4, ladite identification comprenant la détection d’un ou plusieurs signaux à 2,17(1 H), 23,89(130); 176,60(130); 4,63(1H), 104,17(130); 3,68(1H), 78,41(130); 5,09(1H), 76,99(130); 3,78(1H), 79,36(130); 4,10(1 H), 65,96(130); 3,37(1H), 65,95(130); 5,30(1H), 101,16(130); 3,58(1H), 73,93(130); 3,80(1 H), 75,22(130); 3,82(1H), 84,46(130); 4,64(1H), 72,67(130); 3,49(1H), 63,00(130); 177,00(130); 2,30(1 H), 23,37(130); 176,14(130); 5,00(1H), 106,73(130); 3,93(1H), 76,85(130); 5,25(1H), 75,96(130); 4,14(1 H),76,79(130) ;4,29(1 H),65,60(130) ;3,69(1 H),65,60(130) ;5,76(1 H),96,99(130) ;4,31 (1 H),77,76(13C) ; 4,42(1 H), 80,83(130) ; 3,45(1H), 84,04(130) ; 3,92(1 H), 75,71(130) ; 3,48(1 H), 63,61(130) ; 178,44(130). 6. Procédé selon la revendication 4, ladite quantification étant calculée selon la formule %Ac= jC3-XylAc/JZC1-Glc, dans laquelle |C3-XylAc = intégrale du signal de la position 3 du xylose portant le groupe acétyle en 3 et le groupe acide 4-O-méthyl-glucuronique en 2 et jEC1-Glc = intégrale de la somme des signaux de la position C1 du groupe acide 4-O-méthyl-glucuronique, lié au xylose avec un groupe acétyle et lié au xylose sans groupe acétyle. 7. Procédé selon l’une quelconque des revendications précédentes permettant la préparation de polysulfate de pen-tosane. 8. Procédé selon l’une quelconque des revendications précédentes permettant la préparation de xylane. 9. Procédé selon l’une quelconque des revendications précédentes permettant la qualification de polysulfate de pen-tosane à usage pharmaceutique, de matières premières de celui-ci et de produits manufacturés de celui-ci. 10. Polysaccharide de formule
dans laquelle R represente H et G represente H ou acetyle; et au moins 20 % des motifs de xylose substitues par un groupe acide 4-O-methyl-glucuronique ayant egalement G=acetyle. 11. Polysaccharide selon la revendication 10, de 35 % a 70 % des motifs de xylose substitues par un groupe acide 4-O-methyl-glucuronique ayant egalement G=acetyle.
REFERENCES CITED IN THE DESCRIPTION
This list of references cited by the applicant is for the reader’s convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.
Patent documents cited in the description • WO 03073106 A [0026]
Non-patent literature cited in the description • T.ASTRUP. ScandJ Clin Lab Invest, 1952, vol. 137 · Carbohydrate Research, 2002, vol. 337, 373-377 [0006] [0031] • Carbohydrate Polymers, 1991, vol. 16, 211-214 [0026]

Claims (2)

  1. :É^itó.M?riD^áN-i,ouszijLFÁT KÉmiTM&amp;mrnmm< mm :MEI1«¥AÍAIMAK és azok előállítására szolgáló ' ELJÁRÁSOKNAK A MINŐSÍTÉSÉRE S«sfe»<lalmi l|ifíyf>oslék
    1. Eljárás a következő képiem poibzaclwidoknak az előállítására:
    ahol R jelentése Έ vagy Sö#lá (3 jelentése H, $03N» vagyaeetii, ahol az magába» foglal legalább egy lopást, amely azoknak, a t&amp;tfe^gysógeknok. m azonosításából vagy mennyiségi .meghatározásából áll, amelyek szubsztitoálva (helyettesítve) vannak 4‘0-aneuí-glükuronsayval és acetitezebek (Omeeti!}. Eljárás az I, Igénypont szerint, ahö! a poliszsehadd tartalmaz legalább 20%-ban áiiőn-egységeket, amelyek szublimálva (helyettesítve) vanaak ahol azok aceiilezettek (ö:::aceíil), A Eljárás a 2. igénypont szerint, ahol a poliszáéban*! tartalmaz 3;5Netó! 70%-ig xítóz-egységeket, amelyek szubsztimáfva (helyettesítve) vannak 4MÖ*ti£ÍLglükuronsax-vtá, ahol azok aceiilezettek (G-aeetlI). 4* Eljárás az előző igénypontok bármelyike szerint ahol a nevezett lépés, amely azonosításból vagy mennyiségi meghatározásból áll, NME spektroszkópia révén van megvalósítva.
  2. 5, Glfáms a A öv mpcmt vem:, ahol az a onísNtás magiban foglalta og> vag> több jeineEa detektálását u következőknél (azok esetében): 2,17(1 H), 23,89(130: 17{kőÖ(13G); 4,o3tlH), 104,17(130; 3,68(111), 78,41(130; 5.09(10, 76,99(130; 3,78()11), ?9,3M3C); 4JÖ(IIh, 65.96*130; 3,37(1 H), 65,95(130; 5,30(11:1), 101,16(130; 3,58* Ili), 73N303O; 3,80(111), 75,22(130; 3,82(11·!}, 84,46(130; 4,64(111), ΌΌΟ, 3,49(0) M,00(130, 177,000 A'} ΌΟΠΗρ Ό7(ΑΟ, 9&amp;E(H6 \O0(fil). 106,73(130, .0(1 H), >,85(130 \25(1H), N,9o(i30; 48 4(10, 76:79(130; 4,29(11-1), 65,60(13C); 3,99(0), 65,60(13(:): 5,76(1 H), 96,99( 13C); 4,31(11-1), 77,76(1.30; 4,42( IH), 80,83(130); 3,45(1 H). 84,04(130; 3,92(111), 75,71(130; 3,48(1 H), 63,61(130; 178,44(130). i, Eljárás a 4. igénypont szerint, ahol a mennyiségi meghatározás a következő képlet szerint van kiszámítja: NAc IO-X>lAeJICl-Cde, ahol |C3-XylAe - azon xiiös 3-as pozíciójához tartozó jelnek az integrálja^amely az aeetli-esoportoí a 3-ban és a 4-0-mctii-giükuronsavat a 2-ben hordozza, és jXCXGlc ~ azon 4 - 0-; n:u! -gl ük m m m\ Cl-es pozíciójához tartozó jelek összegének az integrálja, amely a xilózhoz acetU-esoportml kapcsolódik vagya xilózhoz acetíl-esoport nélkül kapcsolódik, f. l|iáfás m előző igénypontok bármápte sisriö:| iíSély szolgál |, Eljárás m diai) igénypontok bármelyike szedni antely xilán előállítására szolgái &amp; Eljárás az dozo ipnygodok bármelyike szedni. mwW 'gyógyászati alkalmazásra szolgáló ipstö^án-poHsiulflMak* annak a apw^ÉÉ é§ az abbéi előállított termékeknél &amp;$iin$sité$<lre .ssblgll, dk Políszocharkl amely a következő képkdb
    ahol R jelentése H és G jelentése í! vagy aceük és a 4~0*metíl-glükuronsavval: satitsditnilt Chelptíésltetí) xilőz-egysegek legalább 20%-ban szintén rendelkeznék. GPteétilleL M*· Pollszaeband a 10. igénypont szerint, ahol u 4~0~metil-g1ükbroMavvai sznbsztiMut |helyd:tésített) sitéz-egységek 35%-tól ?Ö%-ig szintén rendelkeznek GS::aeetüiel, Λ
HUE14703299A 2013-01-24 2014-01-23 Eljárás pentozán-poliszulfát készítményeknek, azok nyersanyagainak és azok elõállítására szolgáló eljárásoknak a minõsítésére HUE034910T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000112A ITMI20130112A1 (it) 2013-01-24 2013-01-24 Metodo di qualificazione di preparazioni di pentosan polifosfato, sue materie prime e processi di produzione

Publications (1)

Publication Number Publication Date
HUE034910T2 true HUE034910T2 (hu) 2018-03-28

Family

ID=47749927

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14703299A HUE034910T2 (hu) 2013-01-24 2014-01-23 Eljárás pentozán-poliszulfát készítményeknek, azok nyersanyagainak és azok elõállítására szolgáló eljárásoknak a minõsítésére

Country Status (8)

Country Link
US (2) US10407515B2 (hu)
EP (1) EP2948481B1 (hu)
ES (1) ES2644823T3 (hu)
HU (1) HUE034910T2 (hu)
IT (1) ITMI20130112A1 (hu)
PT (1) PT2948481T (hu)
SI (1) SI2948481T1 (hu)
WO (1) WO2014114723A1 (hu)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102692302B1 (ko) * 2015-05-20 2024-08-07 케미 에스.피.에이. 폴리사카라이드의 제조방법
JP6225321B1 (ja) * 2016-08-31 2017-11-08 王子ホールディングス株式会社 ポリ硫酸ペントサンの製造方法
WO2018043667A1 (ja) 2016-08-31 2018-03-08 王子ホールディングス株式会社 酸性キシロオリゴ糖の製造方法及び酸性キシロオリゴ糖
KR20190093214A (ko) 2016-12-13 2019-08-08 베타 테라퓨틱스 피티와이 리미티드 헤파라나제 억제제 및 그의 용도
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
JP6281659B1 (ja) 2017-02-28 2018-02-21 王子ホールディングス株式会社 ポリ硫酸ペントサン、医薬組成物及び抗凝固剤
SG10201913607WA (en) 2017-05-31 2020-03-30 Oji Holdings Corp Moisturizing topical preparation
BR112020004787A2 (pt) 2017-09-12 2020-09-24 Oji Holdings Corporation polissulfato de pentosano, composição farmacêutica, anticoagulante, e, método para produzir polissulfato de pentosano
PL3730521T3 (pl) 2017-12-20 2023-10-09 Oji Holdings Corporation Polisiarczan pentozanu i lek zawierający polisiarczan pentozanu
CN109793751B (zh) * 2019-01-15 2021-02-26 广西壮族自治区中国科学院广西植物研究所 阿拉伯木聚糖磺酸盐在制备治疗骨关节炎的药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2572731B1 (fr) * 1984-11-07 1987-03-06 Sanofi Sa Nouveaux sulfates de xylanes de bas poids moleculaires, leur procede de preparation et leur activite antithrombotique et hypolipemiante par voie orale
RU2309410C2 (ru) 2002-02-28 2007-10-27 Майкроусенс Байофейдж Лимитед Связывание патологических форм прионовых белков
WO2009087581A1 (en) * 2008-01-04 2009-07-16 Alembic Limited An improved process for the preparation of pentosan polysulfate or salts thereof
WO2012101544A1 (en) * 2011-01-29 2012-08-02 Alembic Pharmaceuticals Limited An improved process for the preparation of pentosan polysulfate or salts thereof
WO2012114349A1 (en) * 2011-02-23 2012-08-30 Cadila Healthcare Limited An improved process for the preparation of pentosan polysulfate sodium

Also Published As

Publication number Publication date
EP2948481A1 (en) 2015-12-02
PT2948481T (pt) 2017-11-01
US10407515B2 (en) 2019-09-10
US20160002365A1 (en) 2016-01-07
ITMI20130112A1 (it) 2014-07-25
US11242412B2 (en) 2022-02-08
EP2948481B1 (en) 2017-09-13
US20200010578A1 (en) 2020-01-09
WO2014114723A1 (en) 2014-07-31
SI2948481T1 (sl) 2017-12-29
ES2644823T3 (es) 2017-11-30

Similar Documents

Publication Publication Date Title
HUE034910T2 (hu) Eljárás pentozán-poliszulfát készítményeknek, azok nyersanyagainak és azok elõállítására szolgáló eljárásoknak a minõsítésére
Gullón et al. Synthesis, optimization and structural characterization of a chitosan–glucose derivative obtained by the Maillard reaction
Song et al. Analysis of the glycosaminoglycan chains of proteoglycans
Holzgrabe et al. Quantitative NMR spectroscopy—applications in drug analysis
Kumirska et al. Application of spectroscopic methods for structural analysis of chitin and chitosan
Khan et al. Reporting degree of deacetylation values of chitosan: the influence of analytical methods
Kono et al. NMR characterization of cellulose acetate: chemical shift assignments, substituent effects, and chemical shift additivity
Jones et al. Heparin characterization: challenges and solutions
HOUNSELL et al. 1H‐NMR studies at 500 MHz of a neutral disaccharide and sulphated di‐, tetra‐, hexa‐and larger oligosaccharides obtained by endo‐β‐galactosidase treatment of keratan sulphate
Wang et al. Structural characterization and in vitro antitumor activity of polysaccharides from Zizyphus jujuba cv. Muzao
Khanal et al. Cryogenic IR spectroscopy combined with ion mobility spectrometry for the analysis of human milk oligosaccharides
Gonzalez-Manzano et al. Flavanol–anthocyanin pigments in corn: NMR characterisation and presence in different purple corn varieties
Keire et al. Characterization of currently marketed heparin products: composition analysis by 2D-NMR
Kono et al. NMR characterization of sodium carboxymethyl cellulose 2: Chemical shift assignment and conformation analysis of substituent groups
Kasaai The use of various types of NMR and IR spectroscopy for structural characterization of chitin and chitosan
EA037102B1 (ru) Способ анализа гликозаминогликанов, гепаринов и их производных методом ямр (ядерного магнитного резонанса)
Bednarek et al. An assessment of polydispersed species in unfractionated and low molecular weight heparins by diffusion ordered nuclear magnetic resonance spectroscopy method
US11474100B2 (en) Chromophore-labeled oligosaccharide markers and methods of use thereof
Han et al. Monosaccharide compositions of sulfated chitosans obtained by analysis of nitrous acid degraded and pyrazolone-labeled products
Nikolić et al. Deconvoluted Fourier-transform LNT-IR study of coordination copper (II) compounds with dextran derivatives
DE69115181T2 (de) Polysaccharid enthaltende Zusammensetzung oder Polysaccharid mit heparinoidaler Aktivität, Verfahren zu ihrer Herstellung und Antikoagulans welche dieses als aktives Ingredienz enthält.
DE69836496T2 (de) Verfahren zur herstellung von beta-(1,3)-d-glukan aus pilzen
Zhao et al. Charting the solid‐state NMR signals of polysaccharides: A database‐driven roadmap
Olennikov et al. A quantitative assay for total fructans in burdock (Arctium spp.) roots
McNeal et al. A novel mass spectrometric procedure to rapidly determine the partial structure of heparin fragments